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To the Editor: Porcine epidemic diarrhea virus (PEDV) 
was first detected in pigs in the United States in May 2013 (1). 
Since then, according to the American Association of Swine 
Veterinarians (https://www.aasv.org, see link to number of 
new cases reported), PEDV has spread to 41 states, and as of 
October 15, 2014, 8,622 confirmed cases of PEDV infection 
have been reported in swine. PEDV (family Coronaviridae, 
genus Alphacoronavirus) is an enveloped, positive-sense, 
single-stranded RNA virus (2). The virus replicates in epithe-
lial cells of small and large intestines and causes highly con-
tagious infection in pigs. The disease is characterized by wa-
tery diarrhea, vomiting (leading to subsequent dehydration), 
and high rates of death, especially in young piglets; thus, out-
breaks cause substantial economic losses to the swine indus-
try (1). Variants of the original virulent PEDV have recently 
been isolated in the United States, making development of a 
vaccine to protect against this devastating disease even more 
challenging (3). Vero cells are used for the isolation of virus 
from clinical samples and for virus propagation and titration 
and virus neutralization studies. The addition of exogenous 
trypsin in culture medium is a prerequisite for efficient rep-
lication of PEDV in Vero cells (4): trypsin cleaves the spike 
protein of PEDV into 2 subunits that mediate cell-to-cell fu-
sion and virus entry into the cells (5).
We examined PEDV replication in a newly established 
immortalized duck intestinal epithelial cell (MK-DIEC) 
line, which was generated from the intestinal tissues of 
a 19- day-old white Pekin duck embryo. MK-DIECs are 
cuboidal (characteristic of epithelial cells), express epithe-
lial marker (pan-cytokeratin), and show extensive prolif-
eration in culture. Several coronaviruses, including PEDV, 
use aminopeptidase N (APN) as the cellular receptor for 
attachment to cells (6). As a first step, we used a rabbit 
polyclonal anti-human APN antibody (Abcam, Cambridge, 
MA, USA) in an indirect immunofluorescence assay (IFA) 
to examine whether MK-DIECs express APN. We found 
that nearly 100% of the cells expressed APN on their sur-
face (online Technical Appendix Figure 1, http://wwwnc.
cdc.gov/EID/article/21/3/14-1658-Techapp1.pdf).
Next, we examined PEDV replication in MK-DI-
ECs. The cells were cultured in medium containing equal 
amounts of Dulbecco modified Eagle medium; Mam-
mary Epithelial Growth Medium (Lonza, Walkersville, 
MD, USA) supplemented with bovine pituitary extract 
(70 µg/mL), human epidermal growth factor (5 ng/mL), in-
sulin (5 µg/mL), and hydrocortisone (0.5 µg/mL); and 2% 
fetal bovine serum. Near confluent cells were infected with 
PEDV at a multiplicity of infection of 0.1. The Colorado 
strain of PEDV (obtained from the National Veterinary 
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Figure. Replication of porcine epidemic diarrhea virus (PEDV) in a newly established immortalized duck intestinal epithelial cell line 
(MK-DIEC) infected with PEDV at a multiplicity of infection of 0.1 in the presence of different concentrations of trypsin. A) Twenty-four 
hours after infection, PEDV nucleoprotein in infected cells was detected by immunofluorescence assay using fluorescein isothiocyanate–
labeled nucleoprotein-specific monoclonal antibody. B) PEDV-induced cytopathic effect in MK-DIEC cells 36 h after infection. 
Services Laboratories, Ames, IA, USA), which was initially 
passaged 5 times in Vero cells, was used to infect the MK-
DIECs. After adsorption for 1 h, the cells were cultured 
in serum-free Dulbecco modified Eagle medium supple-
mented with 0.02% yeast extract, 0.3% tryptose phosphate 
broth, and 1% penicillin/streptomycin (infection medium). 
To examine the requirement of trypsin (Sigma, St. Louis, 
MO, USA) for PEDV replication in MK-DIECs, we added 
trypsin (0, 2.5, 5, or 10 µg/mL) to the infection medium.
We also cultured MK-DIECs in 96-well plates and 
similarly infected them with PEDV for the detection of 
PEDV nucleoprotein (NP) by IFA using fluorescein isothio-
cyanate–labeled mouse PEDV NP monoclonal antibody 
(SD-1F; Medgene Labs, Brookings, SD, USA). At 12, 24, 
and 36 h after infection, released virus in infected cells was 
quantified by virus titration in Vero cells by inoculating 10-
fold serial dilutions. After 24 h, viral NP was detected by 
IFA staining. The virus titer was calculated according to 
the Reed–Muench method and expressed as the 50% tissue 
culture infectious dose/mL.
We detected PEDV NP in MK-DIECs 24 hours after 
infection in medium with and without trypsin (data not 
shown). However, the numbers of cells positive for PEDV 
NP was larger in cells cultured with trypsin (2.5 µg/mL and 
5 µg/mL) than without trypsin (Figure, panel A). PEDV 
also induced cytopathic effects (CPEs) in these cells, 
which were characterized by rounding of cells, syncytium 
formation, and cell detachment. The CPEs were more pro-
nounced in cells infected with added trypsin; as little as 
2.5 µg/mL of trypsin in infection medium was sufficient 
to induce substantial CPEs in infected cells (Figure, panel 
B). No signs of CPEs were observed in uninfected control 
cells, and cells did not display any trypsin-mediated toxic-
ity. The virus titers were detectable in PEDV-infected cells 
12 h after infection. The titers further increased at 24 h, 
reaching a peak at 36 h after infection. Infected cells in in-
fection medium with 10 µg /mL added trypsin had the high-
est titers (online Technical Appendix Figure 2).
Coronaviruses are RNA viruses that are prone to high 
levels of mutation resulting in novel reassortants. Birds and 
bats are considered reservoirs of coronaviruses. However, 
reserviors of PEDV are not yet known. In conclusion, we 
have demonstrated that PEDV replicates in MK-DIECs. 
Availability of a cell line of intestinal origin that supports 
PEDV replication may be of value for studying mecha-
nisms of virus–cell interactions and for developing live at-
tenuated and killed vaccines.
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To the Editor: The unprecedented number of Ebola 
virus disease (EVD) cases in western Africa has compelled 
the world to consider experimental and off-label therapeu-
tics to mitigate the current outbreak. For clinicians, ap-
proved drugs are an attractive solution because of known 
safety profiles and availability.
Oral lamivudine (GlaxoSmithKline, Brentford, UK), 
a US Food and Drug Administration–approved anti-HIV 
drug, has been suggested as a possible antiviral agent 
against Ebola virus (EBOV). In September 2014, a Libe-
rian physician, Dr. Gorbee Logan, reported positive results 
while treating EVD with lamivudine (1). Thirteen of 15 
patients treated with lamivudine survived presumed EVD 
and were declared virus free. Clinical confirmation of EVD 
in these cases remains to be verified.
Our laboratory had previously assessed this antiret-
roviral compound in drug screens against EBOV and ob-
served no discernable antiviral activity. However, given 
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